Gregory Odle Sells 8,433 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) insider Gregory Odle sold 8,433 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $145,469.25. Following the sale, the insider directly owned 187,735 shares of the company’s stock, valued at approximately $3,238,428.75. This represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

OrthoPediatrics Stock Down 3.2%

Shares of OrthoPediatrics stock opened at $16.66 on Thursday. OrthoPediatrics Corp. has a 12-month low of $15.28 and a 12-month high of $26.40. The firm has a market capitalization of $421.16 million, a PE ratio of -9.86 and a beta of 1.07. The company has a quick ratio of 2.65, a current ratio of 5.55 and a debt-to-equity ratio of 0.28. The stock’s fifty day moving average is $17.67 and its 200-day moving average is $17.93.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.11. The business had revenue of $61.61 million during the quarter, compared to analyst estimates of $61.27 million. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%. Equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Key Headlines Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Negative Sentiment: CEO David R. Bailey sold 19,535 shares (~$336,979), reducing his direct stake by ~6.15%. SEC Filing
• Negative Sentiment: CFO Fred Hite sold 12,993 shares (~$224,129), trimming his holding by ~4.47%. SEC Filing
• Negative Sentiment: General Counsel Daniel J. Gerritzen sold 8,614 shares (~$148,592), cutting his stake by ~5.45%. SEC Filing
• Negative Sentiment: Insider Gregory A. Odle sold 8,433 shares (~$145,469), reducing his position by ~4.30%. SEC Filing
• Negative Sentiment: Insider Joseph W. Hauser sold 8,596 shares (~$148,281), decreasing his stake by ~4.23%. SEC Filing

Institutional Trading of OrthoPediatrics

Several institutional investors have recently made changes to their positions in KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares in the last quarter. Millennium Management LLC lifted its position in OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock worth $16,172,000 after buying an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after buying an additional 106,041 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of OrthoPediatrics during the 1st quarter valued at $389,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of OrthoPediatrics during the 2nd quarter valued at $220,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on KIDS. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Truist Financial raised their price objective on shares of OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a research note on Monday, March 2nd. BTIG Research boosted their target price on shares of OrthoPediatrics from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Needham & Company LLC increased their target price on OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Canaccord Genuity Group initiated coverage on OrthoPediatrics in a research report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, OrthoPediatrics currently has an average rating of “Moderate Buy” and an average price target of $24.67.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.